News

LLY is expanding its revenue base beyond Mounjaro and Zepbound with new launches and label expansions that can strengthen long-term growth.

Innovent will take over importing, marketing, and distributing Verzenios in mainland China as generic competition looms

Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from Silicon Valley. Biotechnology has spent decades producing breakthrough medicines, yet drug development has remained painfully slow, often taking 10 to 15 years while roughly 90% of candidates never reach approval. AI is beginning to change that equation. By ... AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity

Deal gives Innovent commercialization rights in mainland China.

The FDA estimates the PreCheck program could save participating companies up to 14 months by reviewing facilities while they are still under construction

June 30 (Reuters) - A bipartisan group of U. lawmakers has opened national security investigations into whether drugmakers Merck and AbbVie have been involved in clinical trials conducted in China that helped fuel the communist country's military capability, according ‌to letters seen by Reuters.

SpaceX recently completed a record IPO.

The weight loss tailwind isn't about to come to a halt.

Micron is now 1.9% of the benchmark index in terms of weight.

Given its significant hedge fund backing and attractive upside potential, NVIDIA Corporation (NASDAQ:NVDA) is one of the most promising robotics stocks. NVIDIA Corporation (NASDAQ:NVDA) is extending its physical AI ambitions on two fronts simultaneously, pushing deeper into industrial robotics safety while advancing its push into agentic life sciences. On June 23, 2026, NVIDIA Corporation (NASDAQ:NVDA) […]

The latest trading day saw Eli Lilly (LLY) settling at $1, representing a +1.81% change from its previous close.

AbbVie (ABBV) - a pharmaceutical company developing and selling specialized therapies - hit a 5-day winning streak, with cumulative gains over this period amounting to 17%. The company's market cap has surged by about $65 Bil over the last 5 days and currently stands at $448 Bil.

This pharma giant's recent run is grabbing headlines, but its long-term behavior tells a more interesting story about portfolio risk.

NVO and VKTX stocks offer contrasting opportunities in the fast-growing obesity market, with key differences in growth, risk and pipeline strength.

LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.

The Nasdaq recorded its fifth straight day of losses on Friday, while the S&P 500 ended marginally lower, with AI-related chip stocks taking a hit, as investors rotated out of major tech stocks and took refuge in defensive assets.

LLY hit a record high after a positive EU panel opinion for Jaypirca and expanded $50/month Medicare access for Zepbound and Foundayo.

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Eli Lilly and Company (NYSE:LLY) is one of the Stocks That Will Make You Rich Over the Next 3 Years. Eli Lilly and Company (NYSE:LLY) has gained roughly 6% over the past 30 days, and the Street expects more than 13.6% upside from the current level. Recently, on June 25, Leerink analyst David Risinger raised […]

Eli Lilly and Company (NYSE:LLY) is among the Best Healthcare Stocks Stocks. On June 23, Reuters reported that Eli Lilly and Company (NYSE:LLY) expects to launch its oral weight-loss drug across Europe and Britain in the second half of 2026 or early 2027. Executive Vice President Patrik Jonsson said the company will start targeting patients paying […]

Eli Lilly and Company (NYSE:LLY) is one of the top trending US stocks to buy now. Eli Lilly and Company (NYSE:LLY) and BioArctic AB announced on June 22 their entry into a research and collaboration agreement regarding a potential new treatment combining BioArctic’s proprietary BrainTransporter technology with an undisclosed Lilly drug candidate in neurodegeneration. Management […]

Eli Lilly and Company (NYSE:LLY) is one of the safe stocks for beginners to buy in 2026. Eli Lilly and Company (NYSE:LLY) received a rating update from Leerink on June 25. The firm lifted the price target on the stock to $1,232 from $1,119 and maintained an Outperform rating on the shares. In a separate development, […]

Eli Lilly's cancer drug Jaypirca received a positive opinion from the European Medicines Agency regarding its use in chronic lymphocytic leukemia. The opinion supports potential use of Jaypirca across all lines of therapy for CLL in Europe. The recommendation is based on Phase 3 clinical trial data and now moves to European Commission review. Eli Lilly (NYSE:LLY) is best known recently for its GLP-1 portfolio, and oncology remains an important part of the business. The EMA's positive view...

Eli Lilly and EZ Corp. lead stocks to watch near buy points this week as investors seek shelter in defensive growth names. The relative strength lines of all top five stocks near buy points are making new highs or near highs. The strong RS lines, which track performance vs. the S&P 500, are especially bullish given the overall uncertain stock market.

Eli Lilly and Company (NYSE:LLY) is one of the high growth stocks to buy right now. On June 14, Eli Lilly announced positive results from the Phase 3 BRUIN CLL-322 clinical trial, which evaluated the addition of Jaypirca (pirtobrutinib) to a time-limited venetoclax and rituximab regimen for patients with relapsed or refractory chronic lymphocytic leukemia/CLL […]

The pharma titan is expanding into new markets.

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 6.3% in the afternoon session after the European Medicines Agency's committee for human medicines backed its cancer drug, Jaypirca, and the company's popular weight-loss treatments were set for inclusion in a new Medicare program.

Here's what investors should do amid the stock market's divergent signals. Eli Lilly is strong while Tesla EV sales loom.

Healthcare stocks were higher late Friday afternoon, with the NYSE Healthcare Index rising 2.2% and